N-acetylcysteine in the Donor, Recipient, or Both Donor and Recipient in Liver Transplantation: A Systematic Review With Meta-analysis and Trial Sequential Analysis.
Journal
Transplantation
ISSN: 1534-6080
Titre abrégé: Transplantation
Pays: United States
ID NLM: 0132144
Informations de publication
Date de publication:
01 09 2023
01 09 2023
Historique:
medline:
23
8
2023
pubmed:
19
4
2023
entrez:
18
4
2023
Statut:
ppublish
Résumé
N-acetylcysteine (NAC) is a potentially effective drug for treating ischemia-reperfusion injury in transplanted livers, but its effect remains controversial. A systematic review and meta-analysis of relevant clinical trials published and registered in the Cochrane Library, MEDLINE, EMBASE, ClinicalTrial.gov , WHO ICTRP, etc, before March 20, 2022 were conducted and registered with PROSPERO (CRD42022315996). Data were pooled using a random effects model or a fixed effects model based on the amount of heterogeneity. Thirteen studies with 1121 participants, 550 of whom received NAC, were included. Compared with the control, NAC significantly reduced the incidence of primary graft nonfunction (relative risk [RR], 0.27; 95% confidence interval [CI], 0.08-0.96), the incidence of postoperative complications (RR, 0.52; 95% CI, 0.41-0.67), the peak postoperative aspartate transferase level (mean difference [MD], -267.52; 95% CI, -345.35 to -189.68), and the peak alanine transferase level (MD, -293.29; 95% CI, -370.39 to -216.20). NAC also improved 2-y (RR, 1.18; 95% CI, 1.01-1.38) graft survival rate. However, NAC increased the intraoperative cryoprecipitate (MD, 0.94; 95% CI, 0.42-1.46) and red blood cell (MD, 0.67; 95% CI, 0.15-1.19) requirements. Moreover, NAC was administered in various modes in these studies, including to the donor, recipient, or both. Subgroup analysis and network meta-analysis showed that NAC administration to recipients could play a more significant role than the other 2 administration modes. Our study supports the protective effect of NAC against LT-induced ischemia-reperfusion injury and shows better clinical outcomes of NAC administration to recipients.
Sections du résumé
BACKGROUND
N-acetylcysteine (NAC) is a potentially effective drug for treating ischemia-reperfusion injury in transplanted livers, but its effect remains controversial.
METHODS
A systematic review and meta-analysis of relevant clinical trials published and registered in the Cochrane Library, MEDLINE, EMBASE, ClinicalTrial.gov , WHO ICTRP, etc, before March 20, 2022 were conducted and registered with PROSPERO (CRD42022315996). Data were pooled using a random effects model or a fixed effects model based on the amount of heterogeneity.
RESULTS
Thirteen studies with 1121 participants, 550 of whom received NAC, were included. Compared with the control, NAC significantly reduced the incidence of primary graft nonfunction (relative risk [RR], 0.27; 95% confidence interval [CI], 0.08-0.96), the incidence of postoperative complications (RR, 0.52; 95% CI, 0.41-0.67), the peak postoperative aspartate transferase level (mean difference [MD], -267.52; 95% CI, -345.35 to -189.68), and the peak alanine transferase level (MD, -293.29; 95% CI, -370.39 to -216.20). NAC also improved 2-y (RR, 1.18; 95% CI, 1.01-1.38) graft survival rate. However, NAC increased the intraoperative cryoprecipitate (MD, 0.94; 95% CI, 0.42-1.46) and red blood cell (MD, 0.67; 95% CI, 0.15-1.19) requirements. Moreover, NAC was administered in various modes in these studies, including to the donor, recipient, or both. Subgroup analysis and network meta-analysis showed that NAC administration to recipients could play a more significant role than the other 2 administration modes.
CONCLUSIONS
Our study supports the protective effect of NAC against LT-induced ischemia-reperfusion injury and shows better clinical outcomes of NAC administration to recipients.
Identifiants
pubmed: 37069635
doi: 10.1097/TP.0000000000004597
pii: 00007890-990000000-00390
doi:
Substances chimiques
Acetylcysteine
WYQ7N0BPYC
Transferases
EC 2.-
Types de publication
Meta-Analysis
Systematic Review
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1976-1990Commentaires et corrections
Type : CommentIn
Informations de copyright
Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.
Déclaration de conflit d'intérêts
The authors declare no funding or conflicts of interest.
Références
Masior L, Grat M. Methods of attenuating ischemia-reperfusion injury in liver transplantation for hepatocellular carcinoma. Int J Mol Sci. 2021;22:8229.
Cannistra M, Ruggiero M, Zullo A, et al. Hepatic ischemia reperfusion injury: a systematic review of literature and the role of current drugs and biomarkers. Int J Surg. 2016;33(Suppl 1):S57–S70.
Liu H, Man K. New insights in mechanisms and therapeutics for short- and long-term impacts of hepatic ischemia reperfusion injury post liver transplantation. Int J Mol Sci . 2021;22:8210.
Sener G, Tosun O, Sehirli AO, et al. Melatonin and N-acetylcysteine have beneficial effects during hepatic ischemia and reperfusion. Life Sci. 2003;72:2707–2718.
Faghfouri AH, Zarezadeh M, Tavakoli-Rouzbehani OM, et al. The effects of N-acetylcysteine on inflammatory and oxidative stress biomarkers: a systematic review and meta-analysis of controlled clinical trials. Eur J Pharmacol. 2020;884:173368.
Ye L, He S, Mao X, et al. Effect of hepatic macrophage polarization and apoptosis on liver ischemia and reperfusion injury during liver transplantation. Front Immunol. 2020;11:1193.
Siu JT, Nguyen T, Turgeon RD. N-acetylcysteine for non-paracetamol (acetaminophen)-related acute liver failure. Cochrane Database Syst Rev. 2020;12:CD012123.
Srinivasan PK, Yagi S, Nagai K, et al. Impact of oxygen free radicals in rat partial liver transplantation. J Surg Res. 2014;191:469–475.
Glantzounis GK, Yang W, Koti RS, et al. Continuous infusion of N-acetylcysteine reduces liver warm ischaemia-reperfusion injury. Br J Surg. 2004;91:1330–1339.
Suakitici S, Guven BB, Tanoglu A, et al. A combination of levosimendan and N-acetylcysteine shows significant favorable efficacy on experimental liver ischemia/reperfusion injury. Ulus Travma Acil Cerrahi Derg. 2021;27:381–388.
Chaves Cayuela N, Kiyomi Koike M, Jacysyn JF, et al. N-acetylcysteine reduced ischemia and reperfusion damage associated with steatohepatitis in mice. Int J Mol Sci. 2020;21:4106.
Koeppel TA, Lehmann TG, Thies JC, et al. Impact of N-acetylcysteine on the hepatic microcirculation after orthotopic liver transplantation. Transplantation. 1996;61:1397–1402.
Slattery KM, Dascombe B, Wallace LK, et al. Effect of N-acetylcysteine on cycling performance after intensified training. Med Sci Sports Exerc. 2014;46:1114–1123.
Santiago FM, Bueno P, Olmedo C, et al. Effect of N-acetylcysteine administration on intraoperative plasma levels of interleukin-4 and interleukin-10 in liver transplant recipients. Transplant Proc. 2008;40:2978–2980.
Khan AW, Fuller BJ, Shah SR, et al. A prospective randomized trial of N-acetyl cysteine administration during cold preservation of the donor liver for transplantation. Ann Hepatol. 2005;4:121–126.
Hu J, Zhang Q, Ren X, et al. Efficacy and safety of acetylcysteine in “non-acetaminophen” acute liver failure: A meta-analysis of prospective clinical trials. Clin Res Hepatol Gastroenterol. 2015;39:594–599.
Moher D, Liberati A, Tetzlaff J, et al. PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009;151:264–9, W64.
Cumpston M, Li T, Page MJ, et al. Updated guidance for trusted systematic reviews: a new edition of the Cochrane Handbook for Systematic Reviews of Interventions. Cochrane Database Syst Rev. 2019;10:ED000142.
Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010;25:603–605.
Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.
Shah A, Smith AF. Trial sequential analysis: adding a new dimension to meta-analysis. Anaesthesia. 2020;75:15–20.
El Gendy H, Elsharnouby N, Koraa A. Perioperative N-acetylcysteine for patients undergoing living donor orthotopic liver transplantation. Ain-Shams J Anaesthesiol. 2015;8:483–490.
Khalili F, Khosravi MB, Sahmeddini MA, et al. The effect of perioperative n-acetylcysteine on the short and long term outcomes in pediatrics undergoing living-donor liver transplantation. Int J Organ Transplant Med. 2021;12:12–20.
Aliakbarian M, Nikeghbalian S, Ghaffaripour S, et al. Effects of N-acetylcysteine addition to University of Wisconsin solution on the rate of ischemia-reperfusion injury in adult orthotopic liver transplant. Exp Clin Transplant. 2017;15:432–436.
Gomez-Gavara C, Moya-Herraiz A, Hervas D, et al. The potential role of efficacy and safety evaluation of N-acetylcysteine administration during liver procurement. The NAC-400 Single Center Randomized Controlled Trial. Transplantation. 2021;105:2245–2254.
Hilmi IA, Peng Z, Planinsic RM, et al. N-acetylcysteine does not prevent hepatorenal ischaemia-reperfusion injury in patients undergoing orthotopic liver transplantation. Nephrol Dial Transplant. 2010;25:2328–2333.
Li X, Wei X, Chen C, et al. N-acetylcysteine inhalation improves pulmonary function in patients received liver transplantation. Biosci Rep. 2018;38:BSR20180858.
Steib A, Freys G, Collin F, et al. Does N-acetylcysteine improve hemodynamics and graft function in liver transplantation? Liver Transpl Surg. 1998;4:152–157.
Thies JC, Teklote J, Clauer U, et al. The efficacy of N-acetylcysteine as a hepatoprotective agent in liver transplantation. Transpl Int. 1998;11(Suppl 1):S390–S392.
Thirunavayakalathil MA, Varghese CT, Bharathan VK, et al. Double-blind placebo-controlled randomized trial of N-acetylcysteine infusion following live donor liver transplantation. Hepatol Int. 2020;14:1075–1082.
D’Amico F, Vitale A, Piovan D, et al. Use of N-acetylcysteine during liver procurement: a prospective randomized controlled study. Liver Transpl. 2013;19:135–144.
Regueira FM, Cienfuegos JA, Pardo F, et al. Improvement in early function of the hepatic graft after treatment of the donor with N-acetylcysteine: clinical study. Transplant Proc. 1997;29:3350–3352.
Weigand MA, Plachky J, Thies JC, et al. N-acetylcysteine attenuates the increase in alpha-glutathione S-transferase and circulating ICAM-1 and VCAM-1 after reperfusion in humans undergoing liver transplantation. Transplantation. 2001;72:694–698.
Cuzzocrea S, Mazzon E, Costantino G, et al. Effects of n-acetylcysteine in a rat model of ischemia and reperfusion injury. Cardiovasc Res. 2000;47:537–548.
Ntamo Y, Ziqubu K, Chellan N, et al. Drug-induced liver injury: clinical evidence of N-acetyl cysteine protective effects. Oxid Med Cell Longev. 2021;2021:3320325.
Bartekova M, Barancik M, Ferenczyova K, et al. Beneficial effects of N-acetylcysteine and N-mercaptopropionylglycine on ischemia reperfusion injury in the heart. Curr Med Chem. 2018;25:355–366.